Persistently high blood sugar and insulin resistance significantly increased the risk of worsening functional and structural heart damage during growth from adolescence to young adulthood, a new study shows. The study was conducted in collaboration between the Baylor College of Medicine in the US, the University of Bern in Switzerland, Murdoch Children’s Research Institute in Australia, the Universities of Bristol and Exeter in the UK, and the University of Eastern Finland. The results were published in the highly esteemed Diabetes…

Survival benefit prevails in low-, intermediate-, and high-risk subgroups Differentiated thyroid cancer patients who receive radioiodine (RAI) treatment after surgery have increased relative survival rates compared to those who do not receive the treatment. According to new research published in the April issue of The Journal of Nuclear Medicine, the clear trend for a higher long-term survival rate is observed in subgroups of patients with low- and intermediate-risk disease, while there is special benefit in high-risk disease. These findings confirm the benefit…

A novel combination of hydroxyl-enriched fullerenol and mTOR inhibitors reveals regulatory mechanisms of organelle communication networks in preclinical models, establishing a synergistic “nanomaterial + metabolic modulation” anticancer strategy. Breakthrough Cancer Strategy Hijacks Tumor Cells’ Survival Network Researchers have developed a nanoparticle-based therapy that disrupts cancer cells’ organelle communication system – the hidden network allowing tumors to resist conventional treatments. By combining multi-hydroxyl fullerene (MF) nanoparticles with mTOR inhibitors, this approach triggers the domino-like collapse of lysosomes (“cellular recycling centers”), mitochondria…

Dana-Farber Brigham Cancer Center-led phase 3 clinical trial shows that pembrolizumab before and after standard-of-care surgery significantly extends event-free survival, representing the first advance for these patients in over 20 years Immunotherapy before and after surgery improves outcomes in head and neck cancer   Dana-Farber Brigham Cancer Center-led phase 3 clinical trial shows that pembrolizumab before and after standard-of-care surgery significantly extends event-free survival, representing the first advance for these patients in over 20 years Patients with locally advanced head…